Stock Library / ALC

ALC Healthcare Latest YouTube: Q2 2026 Published 2026-08-13

Alcon Inc.

Live stock metrics, chart context, a quarter-by-quarter episode archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Latest on YouTube Latest on Spotify Latest on Podbean Apple Podcasts Amazon Music iHeartRadio YouTube Music Company Website Back to Library

Latest earnings video

Alcon (ALC) Q2 2026: A $402M Write-Off And A Lens Line Growing 1%

Published 2026-08-13

Open YouTube Open Spotify Open Podbean Apple Podcasts

Library coverage

Episodes tracked

1

Episodes linked

1

Latest video

Q2 2026

2026-08-13

Podcast available

Yes

Current price

$74.31

+0.41 (+0.55%)

Trailing / Forward P/E

56.73x

Forward: 18.68x

Market cap / Volume

—

Volume: —

Revenue / Earnings Growth

8.7%

Earnings: —

Margins

14.6% op

Gross: 57.2% · Net: 5.9%

Balance sheet

2.09x current

Debt / Equity: 24.5

52-week range / Beta

$61.83 - $90.41

Beta: 0.69

Analyst target

$87.32

Upside: 17.5%

Cash / shareholder return

3.54% FCF yield

Dividend yield: 0.48%

Company context

Industry: Medical Instruments & Supplies

Country: Switzerland

Employees: —

Price to book: 1.67x

Return on equity: 2.9%

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Price chart

Market context for ALC

Competitive view

ALC vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Alcon Inc. latest YouTube video thumbnail

Alcon Inc.

ALC

YouTube Spotify Podbean

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Intuitive Surgical latest YouTube video thumbnail

Intuitive Surgical

ISRG

YouTube Spotify Podbean Apple

Latest video

Q2 2026

Growth profile looks strong right now, with above-average top-line and/or earnings momentum.

Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.

Valuation already asks investors to pay up, so the upside case depends on continued execution staying strong.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Johnson & Johnson latest YouTube video thumbnail

Johnson & Johnson

JNJ

YouTube Podbean Apple

Latest video

Q2 2026

Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.

Profitability is serviceable, but it does not obviously dominate peers on margin or cash conversion alone.

Valuation sits in a middle zone where future upside likely depends more on quarterly execution than on multiple re-rating alone.

Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.

Market Cap

More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.

ALC

$35.92B

Alcon Inc.

ISRG

$142.77B

Intuitive Surgical

JNJ

$629.14B

Johnson & Johnson

Trailing P/E

Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.

ALC

56.7x

Alcon Inc.

ISRG

45.8x

Intuitive Surgical

JNJ

30.3x

Johnson & Johnson

Forward P/E

Forward P/E is often a better read on what investors are paying for the next year of earnings power.

ALC

18.7x

Alcon Inc.

ISRG

33.0x

Intuitive Surgical

JNJ

21.2x

Johnson & Johnson

Revenue Growth

Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.

ALC

8.7%

Alcon Inc.

ISRG

18.5%

Intuitive Surgical

JNJ

6.6%

Johnson & Johnson

Earnings Growth

Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.

ALC

—

Alcon Inc.

ISRG

26.5%

Intuitive Surgical

JNJ

-0.9%

Johnson & Johnson

Operating Margin

Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.

ALC

14.6%

Alcon Inc.

ISRG

33.6%

Intuitive Surgical

JNJ

29.2%

Johnson & Johnson

Gross Margin

Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.

ALC

57.2%

Alcon Inc.

ISRG

66.7%

Intuitive Surgical

JNJ

68.1%

Johnson & Johnson

Net Margin

Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.

ALC

5.9%

Alcon Inc.

ISRG

28.4%

Intuitive Surgical

JNJ

21.5%

Johnson & Johnson

Return on Equity

ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.

ALC

2.9%

Alcon Inc.

ISRG

17.4%

Intuitive Surgical

JNJ

25.7%

Johnson & Johnson

Free Cash Flow Yield

Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.

ALC

3.5%

Alcon Inc.

ISRG

1.8%

Intuitive Surgical

JNJ

2.7%

Johnson & Johnson

Debt to Equity

Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.

ALC

24.54x

Alcon Inc.

ISRG

—

Intuitive Surgical

JNJ

57.71x

Johnson & Johnson

Current Ratio

A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.

ALC

2.09x

Alcon Inc.

ISRG

4.96x

Intuitive Surgical

JNJ

1.09x

Johnson & Johnson

Beta

Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.

ALC

0.69

Alcon Inc.

ISRG

1.46

Intuitive Surgical

JNJ

0.23

Johnson & Johnson

Dividend Yield

Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.

ALC

0.5%

Alcon Inc.

ISRG

—

Intuitive Surgical

JNJ

2.0%

Johnson & Johnson

Analyst Upside

Higher analyst upside suggests the Street still sees room between current price and consensus fair value.

ALC

17.5%

Alcon Inc.

ISRG

20.0%

Intuitive Surgical

JNJ

4.4%

Johnson & Johnson

Related research

Non-quarter videos featuring ALC

Special-topic videos, explainers, and shorts connected to this ticker.

All Research Sections

Shorts and Clips 2026-08-13

ALC Stock: Alcon Q2 2026 Earnings - The Growth Came From The Wrong Line

A fast Charged Alpha clip pointing viewers into the latest earnings coverage.

YouTube

Episode timeline

Episode archive for ALC

Each row is one earnings episode with every verified platform link available.

Q2 2026

Episode live

2026-08-13

Published youtube podcast complete

Alcon (ALC) Q2 2026: A $402M Write-Off And A Lens Line Growing 1%

Quarterly earnings-analysis entry for Alcon Inc.. Use the links on the right to open the video or podcast episode.

YouTube Spotify Podcast Apple Podcasts Amazon Show iHeart Show YouTube Music